Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3735 - RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model


08 Oct 2016


Poster Display


Sara Pilotto


Annals of Oncology (2016) 27 (6): 407-410. 10.1093/annonc/mdw381


S. Pilotto1, M. Simbolo2, I. Sperduti3, S. Novello4, C. Vicentini2, U. Peretti1, S. Pedron2, M. Milella5, A. Mafficini2, P. Visca6, M. Volante7, F. Facciolo8, A. Santo9, M. Infante10, L. Carbognin1, M. Brunelli2, M. Chilosi2, A. Scarpa2, G. Tortora1, E. Bria1

Author affiliations

  • 1 Medical Oncology, AOU Integrata Verona "Borgo Roma", 37134 - Verona/IT
  • 2 Pathology And Diagnostics, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Roma", 37134 - Verona/IT
  • 3 Biostatistic Unit, Istituto Regina Elena, 00144 - Roma/IT
  • 4 Department Of Oncology, University of Turin, Orbassano/IT
  • 5 S. C. Oncologia Medica A, Istituto Regina Elena, 00144 - Roma/IT
  • 6 Anatomia Patologica, Istituto Regina Elena, 00144 - Roma/IT
  • 7 Department Of Oncology, University of Turin, 00000 - Orbassano/IT
  • 8 Thoracic Surgery, Istituto Regina Elena, 00144 - Roma/IT
  • 9 Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Roma", 37134 - Verona/IT
  • 10 Chirurgia Toracica, AOU Integrata Verona, 37138 - Verona/IT


Abstract 3735


We previously validated a clinical risk classification model for resected SqCLC by combining clinicopathological predictors to discriminate patients' (pts) prognosis (Pilotto JTO 2015). Here we investigate the molecular portrait of prognostic outliers to identify differentially expressed, potentially druggable molecular targets (AIRCMFAG project no. 14282).


On the basis of the published 3-class model, 176 and 46 pts with good and poor prognosis, respectively, were identified. Next Generation Sequencing (NGS) analysis (Ion Proton system, Ion Ampliseq custom panel) evaluating Somatic Mutations (SM) and Copy Number Alternations (CNA) of 44 genes was performed; RNA expression, immunohistochemistry (IHC), immunofluorescence (FISH) were performed on Tissue Micro-Arrays (TMA). Descriptive statistics was adopted; continuous variables were dichotomized according to AUC or medians.


The distribution of relevant SM and CNA analysis of 60 pts according to prognosis (good: 27; poor: 33) is reported in the table.

Analysis (NGS) Gene Good: 27 pts [%] Poor: 33 pts [%] p-value
SM PI3KCA 0 3 [9.1] 0.24
NOTCH1 2 [7.4] 0 0.19
CUL3 2 [7.4] 0 0.19
DDR2 3 [11.1] 0 0.085
CDH10 4 [14.8] 1 [3.0] 0.16
CDH1 3 [11.1] 1 [3.0] 0.3
CNA Gains RICTOR 1 [3.7] 9 [27.3] 0.017
SOX2 20 [74.1] 17 [51.5] 0.11
CNA Losses CDKN2A 6 [22.2] 1 [3.0] 0.038
PTEN 11 [40.7] 17 [51.5] 0.57
RB1 8 [29.6] 17 [51.5] 0.12
SMAD4 9 [33.3] 19 [57.6] 0.074

No significant differences in terms of phospho-mTOR and PD-L1 IHC expression were found in the 2 different prognostic subgroups. Patients with concurrent high PD1, SNAI, and Vimentin RNA expression were significantly more likely to be at poor prognosis (p = 0.003).


Although performed on a limited number of pts, the approach to comprehensively analyze DNA, RNA and proteins, using different methodologies, strengthens the clinically relevance of RICTOR/PI3K/mTOR signaling cascade activation in determining the poor prognosis of SqCLC. The possibility to inhibit this pathway with selective agents is currently under investigation in in vitro preclinical models.

Clinical trial identification

Legal entity responsible for the study

University of Verona, Verona, Italy


Associazione Italiana per la Ricerca sul Cancro (AIRC): MFAG Project 14282.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings